TGF-β2/OPTN/FOXC1/miR-200 axis regulates actin dynamics in human trabecular meshwork cells

Area of Science:

• Ophthalmology
• Molecular Biology
• Genetics

Background:

• Glaucoma is a leading cause of irreversible blindness globally.
• Elevated intraocular pressure (IOP) is the primary risk factor for glaucoma.
• Molecular mechanisms regulating IOP remain poorly understood, hindering effective treatment.

Purpose of the Study:

• To investigate the effects of dexamethasone and transforming growth factor beta-2 (TGF-β2) on glaucoma candidate genes in human trabecular meshwork (HTM) cells.
• To elucidate the molecular mechanisms underlying altered IOP and identify potential therapeutic targets.

Main Methods:

• Primary human trabecular meshwork (HTM) cells were treated with dexamethasone or TGF-β2.
• Gene expression and protein interactions related to glaucoma were analyzed.
• The role of microRNAs (miRNAs), specifically the miR-200 family, was investigated.

Main Results:

• FOXC1 represses CYP1B1 expression; optineurin (OPTN) facilitates FOXC1 ubiquitination, inducing CYP1B1.
• The miR-200 family and other miRNAs regulate glaucoma candidate genes.
• TGF-β2 downregulates the miR-200 family, which targets FOXC1, reversibly altering the extracellular matrix.

Conclusions:

• The TGF-β2/OPTN/FOXC1/miR-200 axis is critical for regulating actin dynamics in the anterior eye segment.
• Modulating this pathway offers a potential therapeutic strategy for glaucoma.
• Further research into these molecular mechanisms could lead to novel glaucoma treatments.